{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T08:18:14Z","timestamp":1769501894642,"version":"3.49.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003852","name":"Regione Campania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003852","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.lungcan.2019.07.011","type":"journal-article","created":{"date-parts":[[2019,7,13]],"date-time":"2019-07-13T10:33:17Z","timestamp":1563013997000},"page":"56-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma"],"prefix":"10.1016","volume":"135","author":[{"given":"Francesco","family":"Morra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Merolla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debora","family":"D\u2019Abbiero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gennaro","family":"Ilardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Severo","family":"Campione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Monaco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Guggino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Ambrosio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Staibano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aniello","family":"Cerrato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Visconti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Celetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"475","key":"10.1016\/j.lungcan.2019.07.011_bib0005","first-page":"88","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.lungcan.2019.07.011_bib0010","first-page":"260","article-title":"Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province","volume":"17","author":"Wagner","year":"1960","journal-title":"Br. J. Ind. Med."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0015","doi-asserted-by":"crossref","first-page":"238","DOI":"10.21037\/atm.2017.04.29","article-title":"Mesothelioma: recent highlights","volume":"5","author":"Carbone","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0020","first-page":"162","article-title":"Latency periods in asbestos-related mesothelioma of the pleura","volume":"6","author":"Bianchi","year":"1997","journal-title":"Eur. J. Cancer Prev."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0025","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jtho.2016.04.028","article-title":"Consensus report of the 2015 Weinman international conference on mesothelioma","volume":"11","author":"Carbone","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0030","doi-asserted-by":"crossref","first-page":"12611","DOI":"10.1073\/pnas.1006542107","article-title":"Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation","volume":"107","author":"Yang","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0035","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.ajpath.2013.07.029","article-title":"Continuous exposure to chrysotile asbestos can cause transformation of human mesothelial cells via HMGB1 and TNF-\u03b1 signaling","volume":"183","author":"Qi","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0040","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.ajpath.2012.12.028","article-title":"New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas","volume":"182","author":"Mossman","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0045","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0050","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1183\/09031936.00039510","article-title":"European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer group. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial","volume":"36","author":"Van Schil","year":"2010","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0055","doi-asserted-by":"crossref","first-page":"295","DOI":"10.21037\/tlcr.2017.06.01","article-title":"Novel systemic therapy against malignant pleural mesothelioma","volume":"6","author":"Mancuso","year":"2017","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0060","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"French Cooperative Thoracic Intergroup (IFCT). Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2019.07.011_bib0065","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0070","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1158\/1535-7163.MCT-16-0229","article-title":"Genomic landscape of malignant mesotheliomas","volume":"15","author":"Kato","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0075","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0080","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/JTO.0000000000000436","article-title":"Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study","volume":"10","author":"Lo Iacono","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0085","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0090","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/cge.12630","article-title":"Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases","volume":"89","author":"Rai","year":"2016","journal-title":"Clin. Genet."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0095","doi-asserted-by":"crossref","first-page":"13432","DOI":"10.1073\/pnas.1612074113","article-title":"High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma","volume":"113","author":"Yoshikawa","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0100","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/sj.onc.1201861","article-title":"BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression","volume":"16","author":"Jensen","year":"1998","journal-title":"Oncogene."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0105","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1073\/pnas.1309085110","article-title":"Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair","volume":"111","author":"Yu","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0110","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/ng.2323","article-title":"BAP1 loss defines a new class of renal cell carcinoma","volume":"44","author":"Pe\u00f1a-Llopis","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0115","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1158\/0008-5472.CAN-13-3109","article-title":"Germline mutations in BAP1 impair its function in DNA double-strand break repair","volume":"74","author":"Ismail","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0120","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jtho.2017.03.023","article-title":"A novel BRCA1-associated protein-1 isoform affects response of mesothelioma cells to drugs impairing BRCA1-mediated DNA repair","volume":"12","author":"Parrotta","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0125","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nrm2351","article-title":"Regulation of DNA repair throughout the cell cycle","volume":"9","author":"Branzei","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0130","doi-asserted-by":"crossref","first-page":"6167","DOI":"10.1038\/sj.onc.1210446","article-title":"Involvement of H4(D10S170) protein in ATM-dependent response to DNA damage","volume":"26","author":"Merolla","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.lungcan.2019.07.011_bib0135","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1093\/nar\/gkv061","article-title":"Multiple facets of histone variant H2AX: a DNA double-strand-break marker with several biological functions","volume":"43","author":"Turinetto","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036177","article-title":"Loss of CCDC6, the first identified RET partner gene, affects pH2AX S139 levels and accelerates mitotic entry upon DNA damage","volume":"7","author":"Merolla","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2019.07.011_bib0145","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1002\/ijc.31106","article-title":"CCDC6: the identity of a protein known to be partner in fusion","volume":"142","author":"Cerrato","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.lungcan.2019.07.011_bib0150","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0092-8674(90)90659-3","article-title":"PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas","volume":"60","author":"Grieco","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.lungcan.2019.07.011_bib0155","doi-asserted-by":"crossref","first-page":"28929","DOI":"10.18632\/oncotarget.4325","article-title":"Identification and characterization of RET fusions in advanced colorectal cancer","volume":"6","author":"Le Rolle","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2019.07.011_bib0160","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nm.2658","article-title":"RET, ROS1 and ALK fusions in lung cancer","volume":"18","author":"Takeuchi","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0165","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/sj.onc.1206981","article-title":"H4 (D10S170), a gene frequently rearranged with RET in papillary thyroid carcinomas: functional characterization","volume":"23","author":"Celetti","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.lungcan.2019.07.011_bib0170","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/ijc.29263","article-title":"New therapeutic perspectives in CCDC6 deficient lung cancer cells","volume":"136","author":"Morra","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.lungcan.2019.07.011_bib0175","doi-asserted-by":"crossref","first-page":"12697","DOI":"10.18632\/oncotarget.3708","article-title":"FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC","volume":"6","author":"Morra","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2019.07.011_bib0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049298","article-title":"Identification of sumoylation sites in CCDC6, the first identified RET partner gene in papillary thyroid carcinoma, uncovers a mode of regulating CCDC6 function on CREB1 transcriptional activity","volume":"7","author":"Luise","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2019.07.011_bib0185","doi-asserted-by":"crossref","first-page":"15628","DOI":"10.18632\/oncotarget.3858","article-title":"Ccdc6 knock-in mice develop thyroid hyperplasia associated to an enhanced CREB1 activity","volume":"6","author":"Leone","year":"2015","journal-title":"Oncotarget."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0190","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/nmeth.2131","article-title":"A high-throughput approach for measuring temporal changes in the interactome","volume":"9","author":"Kristensen","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.lungcan.2019.07.011_bib0195","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/j.1365-2559.2012.04313.x","article-title":"Overexpression of chromatin assembly factor-1 p60, poly(ADP-ribose) polymerase 1 and nestin predicts metastasizing behaviour of oral cancer","volume":"61","author":"Mascolo","year":"2012","journal-title":"Histopathology"},{"key":"10.1016\/j.lungcan.2019.07.011_bib0200","doi-asserted-by":"crossref","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0205","doi-asserted-by":"crossref","first-page":"E443","DOI":"10.3390\/ijms18020443","article-title":"FKBP51 immunohistochemical expression: a new prognostic biomarker for OSCC?","volume":"18","author":"Russo","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0210","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/227680a0","article-title":"Cleavage of structural proteins during the assembly of the head of bacteriophage T4","volume":"227","author":"Laemli","year":"1970","journal-title":"Nature."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0215","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1073\/pnas.76.9.4350","article-title":"Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications","volume":"76","author":"Towbin","year":"1979","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0220","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/0168-9525(96)10019-6","article-title":"Genetic manipulation of genomes withrare-cutting endonucleases","volume":"12","author":"Jasin","year":"1996","journal-title":"Trends Genet."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0225","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature24451","article-title":"Molecular basis of USP7 inhibition by selective small-molecule inhibitors","volume":"550","author":"Turnbull","year":"2017","journal-title":"Nature"},{"issue":"345","key":"10.1016\/j.lungcan.2019.07.011_bib0230","first-page":"58","article-title":"A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance","volume":"22","author":"Chauhan","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lungcan.2019.07.011_bib0235","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.lungcan.2016.06.015","article-title":"USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs","volume":"107","author":"Malapelle","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2019.07.011_bib0240","doi-asserted-by":"crossref","first-page":"31815","DOI":"10.18632\/oncotarget.16463","article-title":"The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells","volume":"8","author":"Morra","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.lungcan.2019.07.011_bib0245","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13046-019-1087-1","article-title":"CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer","volume":"38","author":"Morra","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0250","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00280-017-3401-y","article-title":"Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition","volume":"80","author":"Srinivasan","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0255","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0260","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1158\/1078-0432.CCR-07-4953","article-title":"Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin","volume":"14","author":"Evers","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0265","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13046-016-0456-2","article-title":"Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic","volume":"35","author":"Cerrato","year":"2016","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2019.07.011_bib0270","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12943-018-0799-8","article-title":"The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer","volume":"17","author":"Cerrato","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.lungcan.2019.07.011_bib0275","doi-asserted-by":"crossref","first-page":"T107","DOI":"10.1530\/ERC-17-0120","article-title":"Fighting tubulin-targeting anticancer drug toxicity and resistance","volume":"24","author":"Visconti","year":"2017","journal-title":"Endocr. Relat. Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500219305513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500219305513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:32:56Z","timestamp":1759235576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500219305513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":55,"alternative-id":["S0169500219305513"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.07.011","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}